EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 22 / No 2 (Février 2006) Med Sci (Paris), 22 2 (2006) 178-182 References
Free Access
Issue
Med Sci (Paris)
Volume 22, Number 2, Février 2006
Page(s) 178 - 182
Section M/S revues
DOI https://doi.org/10.1051/medsci/2006222178
Published online 15 February 2006
  1. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365 : 687–701. [Google Scholar]
  2. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis : from fields to cancer. Oncogene 2003; 22 : 3081–6. [Google Scholar]
  3. Nelson MA, Radmacher MD, Simon R, et al. Chromosome abnormalities in malignant melanoma : clinical significance of nonrandom chromosome abnormalities in 206 cases. Cancer Genet Cytogenet 2000; 122 : 101–9. [Google Scholar]
  4. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353 : 2135–47. [Google Scholar]
  5. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60 : 1968–73. [Google Scholar]
  6. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163 : 1765–70. [Google Scholar]
  7. Van Dijk M, Sprenger S, Rombout P, et al. Distinct chromosomal aberrations in sinonasal mucosal melanoma as detected by comparative genomic hybridization. Genes Chromosomes Cancer 2003; 36 : 151–8. [Google Scholar]
  8. Chudnovsky Y, Adams AE, Robbins PB, et al. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 2005; 37 : 745–9. [Google Scholar]
  9. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002; 62 : 3200–6. [Google Scholar]
  10. Hoglund M, Gisselsson D, Hansen GB, et al. Dissecting karyotypic patterns in malignant melanomas : temporal clustering of losses and gains in melanoma karyotypic evolution. Int J Cancer 2004; 108 : 57–65. [Google Scholar]
  11. Balazs M, Adam Z, Treszl A, et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry 2001; 46 : 222–32. [Google Scholar]
  12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 : 949–54. [Google Scholar]
  13. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10 : 1753–7. [Google Scholar]
  14. Sharma A, Trivedi NR, Zimmerman MA, et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 2005; 65 : 2412–21. [Google Scholar]
  15. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004; 64 : 2338–42. [Google Scholar]
  16. Laud K, Kannengiesser C, Avril MF, et al. BRAF as a melanoma susceptibility candidate gene ? Cancer Res 2003; 63 : 3061–5. [Google Scholar]
  17. Kumar R, Angelini S, Czene K, et al. BRAF mutations in metastatic melanoma : a possible association with clinical outcome. Clin Cancer Res 2003; 9 : 3362–8. [Google Scholar]
  18. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003; 95 : 1878–90. [Google Scholar]
  19. Davison JM, Rosenbaum E, Barrett TL, et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103 : 788–92. [Google Scholar]
  20. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003; 63 : 5198–202. [Google Scholar]
  21. Bollag G, Freeman S, Lyons JF, Post LE. Raf pathway inhibitors in oncology. Curr Opin Investig Drugs 2003; 4 : 1436–41. [Google Scholar]
  22. Cruz F, Rubin BP, Wilson D, et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 2003; 63 : 5761–6. [Google Scholar]
  23. Schaffer JV, Bolognia JL. The melanocortin-1 receptor : red hair and beyond. Arch Dermatol 2001; 137 : 1477–1485. [Google Scholar]
  24. Sturm RA, Teasdale RD, Box NF. Human pigmentation genes : identification, structure and consequences of polymorphic variation. Gene 2001; 277 : 49–62. [Google Scholar]
  25. Matichard E, Verpillat P, Meziani R, et al. Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure. J Med Genet 2004; 41 : e13. [Google Scholar]
  26. Radhi JM. Malignant melanoma arising from nevi, p53, p16, and Bcl-2 : expression in benign versus malignant components. J Cutan Med Surg 1999; 3 : 293–7. [Google Scholar]
  27. Soto JL, Cabrera CM, Serrano S, Lopez-Nevot MA. Mutation analysis of genes that control the G1/S cell cycle in melanoma : TP53, CDKN1A, CDKN2A, and CDKN2B. BMC Cancer 2005; 5 : 36. [Google Scholar]
  28. Mikhail M, Velazquez E, Shapiro R, et al. PTEN expression in melanoma : relationship with patient survival, Bcl-2 expression, and proliferation. Clin Cancer Res 2005; 11 : 5153–7. [Google Scholar]
  29. Liaw D, Marsh DJ, Li J, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16 : 64–7. [Google Scholar]
  30. Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma : a global perspective. Arch Dermatol 2001; 137 : 1493–6. [Google Scholar]
  31. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264 : 436–40. [Google Scholar]
  32. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368 : 753–6. [Google Scholar]
  33. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8 : 15–21. [Google Scholar]
  34. Chin L. The genetics of malignant melanoma : lessons from mouse and man. Nat Rev Cancer 2003; 3 : 559–70. [Google Scholar]
  35. Tsao H, Zhang X, Kwitkiwski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. Arch Dermatol 2000; 136 : 1118–22. [Google Scholar]
  36. Gillanders E, Juo SH, Holland EA, et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 2003; 73 : 301–13. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.